Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study.
BACKGROUND
The aim of this study was to evaluate the survival benefit of radical surgery with additional extensive upper abdominal procedures (EUAS) for the treatment of stage IIIC and IV ovarian cancer with bulky upper abdominal disease (UAD).


METHODS
An observational study was conducted between 2009 and 2012 involving two different surgical teams. Team A was composed of the "believers" in EUAS and Team B the "non-believers" in EUAS. Patients were divided into a radical surgery group (EUAS group) or a standard surgery group (non-EUAS group) according to whether or not they had received EUAS. All patients underwent primary cytoreductive surgery with the goal of optimal debulking (≤ 1 cm); this was reviewed in the pelvis, middle abdomen, and upper abdomen. The baseline for the two groups was optimal cytoreduction in both the pelvis and middle abdomen. Progression-free survival (PFS) was evaluated.


RESULTS
Radical surgery was performed in 70.7% (82/116) and 12.7% (30/237) of the patients by Teams A and B, respectively. The study groups had similar clinicopathologic characteristics. The median PFS and OS were significantly improved in the radical surgery group, compared with standard surgery groups (PFS: 19.5 vs. 13.3 months, HR: 0.61; 95% CI: 0.46-0.80, P < 0.001; OS: not reached vs. 39.3 months, HR: 0.47; 95% CI: 0.30-0.72, P < 0.001). Positive predictors of complete cytoreduction were treatment with neoadjuvant chemotherapy, improved American Society of Anesthesiologists performance status, and the absence of bowel mesenteric carcinomatosis.


CONCLUSIONS
Radical surgery lengthens the PFS and overall survival times of ovarian cancer patients with bulky UAD. However, a well-designed randomized trial is needed to confirm the present results.
Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. yulan_ren@yahoo.com.
Yulan
Y
Ren
Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. rong_junzhu@aliyun.com.|Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. rong_junzhu@aliyun.com.
Rong
R
Jiang
Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. yinshengyinsheng@126.com.
Sheng
S
Yin
Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. youchao8888@aliyun.com.
Chao
C
You
Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. Fudanliudongli@126.com.
Dongli
D
Liu
Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. Cheng_xi1@sina.com.
Xi
X
Cheng
Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. zhangtang125@126.com.
Jie
J
Tang
Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. ryzang@yahoo.com.|Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. ryzang@yahoo.com.
Rongyu
R
Zang
D000005:Abdomen / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D065426:Cytoreduction Surgical Procedures / Q000009:adverse effects / Q000379:methods* / Q000401:mortality / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000473:pathology / Q000601:surgery*; D011183:Postoperative Complications / Q000453:epidemiology